Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LYEL 
Lyell Immunopharma Inc (LYEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LYEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.87% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 253.97M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 4 | Beta -0.2 | 52 Weeks Range 7.65 - 32.00 | Updated Date 09/17/2025 |
52 Weeks Range 7.65 - 32.00 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -541212.5% |
Management Effectiveness
Return on Assets (TTM) -25.39% | Return on Equity (TTM) -76.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23779090 | Price to Sales(TTM) 4232.87 |
Enterprise Value 23779090 | Price to Sales(TTM) 4232.87 | ||
Enterprise Value to Revenue 396.32 | Enterprise Value to EBITDA 0.25 | Shares Outstanding 19211200 | Shares Floating 12047345 |
Shares Outstanding 19211200 | Shares Floating 12047345 | ||
Percent Insiders 20.56 | Percent Institutions 50.02 |
Upturn AI SWOT
Lyell Immunopharma Inc
Company Overview
History and Background
Lyell Immunopharma Inc. was founded in 2018. It is a clinical-stage T-cell reprogramming company focused on developing therapies for solid tumors. The company has evolved from its foundational science to clinical trials and partnerships.
Core Business Areas
- R&D: Research and development of T-cell reprogramming technologies to address T-cell exhaustion and tumor-induced immune suppression. Focus on solid tumors.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its T-cell therapies in various solid tumor types.
- Manufacturing: Developing and scaling up manufacturing processes for its T-cell therapies.
Leadership and Structure
Liz Homans is the Chief Executive Officer. The company has a board of directors and a management team overseeing research, development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Lyl-CEL: Lyellu2019s lead product candidate, an autologous T-cell therapy reprogrammed with the company's Epi-Ru2122 technology. Designed to address T-cell exhaustion. Currently in Phase 1 clinical trials for solid tumors. Market share is not yet applicable. Competitors: Iovance Biotherapeutics (IOVA), Adaptimmune Therapeutics (ADAP).
- RNR-CEL: Another autologous T-cell therapy reprogrammed with the company's Gen-Ru2122 technology. Designed to address tumor-induced immune suppression. Currently in Phase 1 clinical trials. Market share is not yet applicable. Competitors: Allogene Therapeutics (ALLO), CRISPR Therapeutics (CRSP).
Market Dynamics
Industry Overview
The industry is characterized by rapid innovation, high regulatory hurdles, and significant unmet medical needs in solid tumor treatment. The immunotherapy market is growing, with increasing interest in cell-based therapies.
Positioning
Lyell is positioned as an innovator in T-cell reprogramming, focusing on overcoming key limitations of existing cell therapies for solid tumors. Competitive advantages include its proprietary Epi-R and Gen-R technologies.
Total Addressable Market (TAM)
The TAM for solid tumor therapies is estimated to be in the tens of billions of dollars annually. Lyell is positioned to capture a portion of this market with its novel T-cell reprogramming technologies, addressing limitations in other treatment options.
Upturn SWOT Analysis
Strengths
- Proprietary T-cell reprogramming technologies (Epi-R and Gen-R)
- Focus on addressing unmet needs in solid tumor therapy
- Strong scientific team
- Established partnerships with academic institutions
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on clinical trial outcomes
- Relatively small market capitalization
Opportunities
- Positive clinical trial results for Lyl-CEL and RNR-CEL
- Expansion of pipeline into new solid tumor indications
- Strategic partnerships with pharmaceutical companies
- Advancements in T-cell therapy manufacturing
Threats
- Clinical trial failures
- Competition from established immunotherapy companies
- Regulatory setbacks
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- IOVA
- ADAP
- ALLO
- CRSP
Competitive Landscape
Lyell has a competitive advantage in its T-cell reprogramming technologies, but faces competition from established players with approved products and broader pipelines.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been primarily in terms of research and development progress and expansion of its clinical pipeline.
Future Projections: Future growth depends on the success of its clinical trials and potential partnerships. Analyst estimates are varied, reflecting the inherent uncertainty in biotechnology.
Recent Initiatives: Focus on advancing Lyl-CEL and RNR-CEL through clinical trials, optimizing manufacturing processes, and exploring new T-cell reprogramming strategies.
Summary
Lyell Immunopharma is a clinical-stage biotech company with innovative T-cell reprogramming technologies targeting solid tumors. Its success hinges on positive clinical trial results for its lead product candidates. The company has a strong cash position but a high cash burn rate. Investment carries significant risk due to the nature of biotechnology and clinical development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lyell Immunopharma Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence. Market share data for clinical-stage companies is limited.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lyell Immunopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-06-17 | President, CEO & Director Dr. Lynn Seely M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 300 | Website https://www.lyell.com |
Full time employees 300 | Website https://www.lyell.com | ||
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.